From what I understand, their size and balance sheet typically presents a conflict of interest due to who owns debt, but I'm having some trouble fully understanding and would really appreciate an explanation.
| +189 | Americas M&A League Table Q2 Updated | 75 | 15h |
| +142 | New Article: Dramatic Slide as UBS #22 (US) & New Leadership Desperately Needed | 36 | 8h |
| +118 | Restructuring: Anti-climactic Experience | 31 | 10h |
| +87 | IB Net Worth / Savings Check | 41 | 4m |
| +75 | A COMPLETE GUIDE TO SUMMER INTERNSHIP RECRUITING | 12 | 2d |
| +57 | Woman who emptied Knicks trashcan on street then stole it was DEI exec, worked at JPMorgan Chase | 12 | 13h |
| +51 | Boutique firm wants access to my LinkedIn? | 40 | 1d |
| +40 | Investment Banking is Hard | 17 | 1d |
| +31 | PWP vs BofA | 24 | 6h |
| +30 | AI + Financial Modelling | 8 | 1m |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Because RX is for NERDS and we are BB CHADS
Imagine BB originates bank loan tranche to CrapCo.
CrapCo is in finance stress. Are they going to retain the BB as a debtor-focuses RX group? Obviously not, cause the bank isn’t about to negotiate against itself to cut its own exposure and take a loss. Similar, are the holders of other tranches going to retain the bank as a creditor-focuses RX group? Obviously not, cause the bank isn’t about to argue to allocate value away from the bank loan tranche.
Maybe when private debt funds complete overtake leveraged loan issuers we will see BB RX groups (being somewhat sarcastic)
Thanks. I understand now.
RX is a somewhat esoteric skillset and building it out at a bank would require a huge amount of time and money invested. RX groups also don't generate the same level of fees as BB coverage groups which get both M&A and financing fees. BBs' strengths are their balance sheets which they can't monetize in RX processes outside of providing DIP financing, which they already have desks that do that, and even in that case there would be an inherent conflict between an RX advisor and a DIP financing desk. So there really isn't a huge incentive for them to do so, and notable conflicts. It's just not something that really lends itself to BBs.
Because it’s a conflict of interest.
GS has an RX team
Explicabo qui et minus facilis quidem et et voluptatem. Natus enim quia sed dolores at corrupti repellat. Deleniti aut est id qui sit et voluptatem repudiandae.
Possimus eaque deserunt unde aut. Mollitia quis magnam eum consequatur incidunt saepe. Et ea totam rerum rem fuga ullam. Nostrum quis cupiditate incidunt neque.
Deleniti ea est natus mollitia accusamus molestiae labore. Dolor dolores ea odit veniam unde. Doloribus quae blanditiis consectetur at.
Vel consequuntur ab vel molestiae sequi natus cumque. Illum consequuntur ipsum rerum. Vitae consequatur qui quis vero. Corporis aut magnam eos minus fuga. Necessitatibus modi perferendis impedit unde voluptatibus iusto in.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...